High doses of BACE1 inhibitors stymie synaptic activity in mice. Researchers recommend careful dosing in clinical trials.
Protein touted as a peripheral monocyte receptor that worsens amyloid plaque pathology in transgenic mice.
Medication blocks molecular transporters that eject riluzole from the nervous system.
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.
A sense of change on all fronts pervaded the Clinical Trials on Alzheimer’s Disease conference. Scientists shared their early experiences of what works and what does not as they begin trials with newly defined cohorts, new diagnostic criteria, and new outcomes.
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
The amino terminus toggles between a neatly folded nucleic acid-binding domain and a disorganized configuration that forms inclusions.
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
At CTAD, former FDA neurology leader Rusty Katz urged Alzheimer’s trialists to stop fussing over disease progression. He recommended going after a large effect, regardless of whether it can garner a label of disease modification. That, he says, may mean combination trials.
A CAP symposium opened the CTAD conference, indicating that presymptomatic treatment and “federated” research have become mainstream thinking in Alzheimer’s therapy development. EPAD is pulling together European sites.
Researchers at CTAD reported seeing biomarkers budge in active and passive immunotherapy trials, but measurement techniques and screening protocols still need improvement for early stage trials to succeed.
Researchers at CTAD announced the end for two active immunotherapies, along with the curious story of a placebo as a treatment and the start of a new antibody.
Using creative ways of mining genetic data, researchers are coming up with new risk variants for Alzheimer’s.
Chemical mutagenesis yields an SOD1 variant found in people with the disease. Neurons degenerate without overexpression of the enzyme.